AN 0128

Drug Profile

AN 0128

Alternative Names: AN-0128; Borinic acid ester - Anacor; CRM-0005; ONT-0001

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antibacterials; Organic boron compounds; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acne; Atopic dermatitis; Psoriasis; Rosacea; Staphylococcal infections

Most Recent Events

  • 29 Mar 2011 No development reported - Phase-I/II for Psoriasis in USA (Topical)
  • 29 Mar 2011 No development reported - Phase-II for Acne in USA (Topical)
  • 29 Mar 2011 No development reported - Phase-II for Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top